DNSP-11

DNSP-11 (Dopamine Neuron Stimulating Peptide-11) is an eleven-amino-acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). GDNF itself is one of the most potent known survival factors for dopaminergic neurons and has been investigated extensively in clinical trials for Parkinson's disease — but its large size, instability, and difficult brain-delivery profile have limited its clinical success. DNSP-11 was developed by Don Gash's group at the University of Kentucky as a small, stable, drug-like peptide that retains the dopaminergic-neuroprotective activity of the parent GDNF molecule.

In preclinical studies, DNSP-11 has demonstrated dopaminergic neuroprotection in 6-hydroxydopamine-lesioned rat models of Parkinson's disease and in MPTP-treated non-human primates, increasing dopamine production and improving motor function. The peptide appears to act through a partially distinct mechanism from GDNF, possibly involving direct interaction with cell-surface receptors other than RET / GFRα1 (which mediate GDNF's effects).

Phase 1 clinical trials of intracerebroventricular DNSP-11 in Parkinson's patients were planned at the University of Kentucky. The compound remains in early-stage development and is sold by some research-peptide vendors for use in cell culture and animal models. Human safety data is essentially absent outside of any small clinical safety trial output.

DNSP-11 was identified by Don Gash and colleagues at the University of Kentucky in the mid-2000s as a bioactive fragment of the GDNF pro-region. The team's prior work on GDNF's clinical application in Parkinson's motivated the search for smaller, more drug-like analogs that could be delivered to the brain via less invasive routes. Preclinical efficacy was demonstrated in the late 2000s and 2010s. The peptide has not yet been approved for any clinical use.